CLAIMS

1. A composition that comprises a compound against epidermal growth factor receptor (EGFR) and a vaccine against a N-glycolyl GM3 ganglioside (NeuGcGM3) for use in the treatment of cancer.

2. The composition of claim 1 wherein the compound against the EGF receptor is a monoclonal antibody that recognizes the EGFR.

3. The composition of claim 2 wherein the monoclonal antibody that recognizes the EGFR is nimotuzumab.

4. The composition of claim 1 wherein the compound against the EGFR is an anti-EGFR vaccine.

5. The composition of claim 1 wherein the vaccine has NeuGcGM3/very small size particle as active principle.

6. The composition of claim 1 wherein the vaccine is racotumumab anti-idiotypic vaccine adjuvated with alumina.

7. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.

8. The composition of claim 7 wherein the tumor is a cancer selected from the group comprising non-small cell lung cancer, stomach, colorectal, pancreas, liver, bladder, glioblastoma, sarcomas and non-Hodgkin lymphoma.

CLAIMS

1. A pharmaceutical composition for treating a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets, comprising:

   - Nimotuzumab monoclonal antibody; and

   - a compound against the NeuGcGM3 ganglioside being vaccine having NeuGcGM3/VSSP as active principle or Racotumumab anti-idiotypic vaccine adjuvated with alumina.

2. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.

3. The composition of claim 2 wherein the tumor is a cancer selected from the group comprising non-small cell lung cancer, stomach, colorectal, pancreas, liver, bladder, glioblastoma and non-Hodgkin lymphoma.

4. The composition of claims 1 to 3 in combination with conventional radiotherapy.

5. The composition of claims 1 to 3 in combination with conventional chemotherapy.

6. The composition of claims 1 to 3 in combination with conventional radiotherapy and chemotherapy.